Aidex

Quick links to important sections

Aidex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aidex

Quick Facts

Property Description
Active Ingredient Rasagiline (as the tartrate salt)
Form Oral tablet (Immediate Release)
Pharmacological Class Monoamine Oxidase (MAO) Type B Inhibitor
General Purpose Managing symptoms related to reduced dopamine levels
Origin Synthetic, small molecule

What Type of Medicine is Aidex?

Aidex is a synthetic, prescription-only medication chemically classified as an irreversible Monoamine Oxidase (MAO) type B inhibitor, which belongs to the larger group of dopaminergic antiparkinsonism agents. The drug is supplied as an oral tablet for oral administration and contains one active compound, Rasagiline. This substance is formulated as the tartrate salt to maintain stability and ensure pharmaceutical quality. The final product is manufactured as the highly purified R(+)-enantiomer, which is the isomer responsible for the therapeutic activity.

How Does Aidex Generally Help?

The medicine's general therapeutic function is to assist in managing conditions characterized by a functional reduction of the neurotransmitter dopamine in the central nervous system. It achieves this by the selective and permanent inhibition of the MAO-B enzyme. This action helps increase and stabilize dopamine levels, which is the desired outcome for improving motor function and control. By blocking the action of the enzyme, Aidex prevents the rapid metabolic degradation of dopamine, effectively augmenting the signaling of the brain's naturally produced supply. This indirect action of dopamine preservation is clinically recognized for providing consistent support for motor control.

Regulatory References

  1. European Medicines Agency (EPAR)
  2. EMA EPAR for Azilect (Rasagiline)

What side effects are possible with Aidex?

Possible Side Effects and Safety Information

The Aidex Continuous Glucose Monitoring System (CGMS) is a medical device for tracking glucose trends. Its safety profile is primarily related to the risks of device performance, sensor placement, and specific limitations in patient populations, rather than traditional pharmacological side effects.

Adverse Reaction Scope

  • Serious Adverse Reactions: The most clinically significant risks involve inaccurate glucose readings that may lead to inappropriate treatment decisions, potentially resulting in severe hypoglycemia or hyperglycemia (such as Diabetic Ketoacidosis—DKA). Inaccuracies are explicitly linked to rapid changes in blood glucose (exceeding 0.1 mmol/L per minute or 1.8 mg/dL per minute) or severe dehydration.
  • Systemic and Local Adverse Reactions: Adverse events related to the device itself primarily affect the skin and subcutaneous tissue at the insertion site. These may include localized reactions such as bleeding, irritation, pain, or inflammation.

Safety Restrictions and Contraindications

The use of the Aidex CGMS is subject to specific safety limitations defined in official documents:

Classification Detail
Contraindicated Populations Individuals under the age of 14 or those incapable of self-administering diabetes therapy, or who require strict professional supervision for CGMS use. Also contraindicated in patients with severe mental disorders, alcoholism, drug abuse, unconsciousness, or severe sensory impairment (hearing or vision) that prevents recognizing device alerts.
Exposure and Testing Limitations The CGMS must be completely removed before any Magnetic Resonance Imaging (MRI) scan. The performance is not evaluated for women with gestational diabetes or when used with other implantable medical devices like a pacemaker.
Context of Use Restriction The CGMS readings serve only as a reference for supplemental monitoring and must not be used as the sole basis for making treatment adjustments (e.g., insulin dosing) without confirmation from a fingertip blood glucose test, especially when symptoms do not match the reading.

Summary

Understanding the safety profile for Aidex involves recognizing that its accuracy is compromised under certain physiological states, and that proper use requires adherence to all specified safety restrictions and limitations to mitigate the risk of clinical error. The safety notes clearly establish the device as an adjunctive tool to complement, not replace, standard blood glucose monitoring.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the Aidex (Rasagiline) overdose profile by its potential for life-threatening outcomes and delayed symptom presentation. Clinical manifestations listed in labeling include severe central nervous system (CNS) effects such as seizures, confusion, agitation, muscle spasms, and hallucinations. Cardiovascular signs documented are a rapid or irregular pulse, severe headache, and extremely high blood pressure.

Life-Threatening Risks

Suspected overdose necessitates immediate medical attention due to the explicit risk of developing Serotonin Syndrome and Hypertensive Crisis.

Symptom Onset Warning Required Emergency Action
Symptoms may be delayed for 12 to 48 hours, requiring extended monitoring. Seek emergency medical attention immediately for any suspected overdose.

Mandated Emergency Actions

The labeling requires contacting emergency services immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Management of overdose is strictly symptomatic and supportive, as no specific antidote is known. Close monitoring of body temperature is a documented supportive measure, especially given the risk of Serotonin Syndrome.

Therapeutic Uses of Aidex

What Aidex Treats: Main Uses and Benefits

Aidex (Rasagiline) is commonly used to help with symptoms that interfere with daily functioning, specifically in conditions characterized by periods of heightened symptoms. It is relevant for easing symptom clusters associated with movement. The medication is used for symptomatic support in conditions presenting with acute episodes, and as an add-on treatment for conditions involving episodic or fluctuating manifestations.


Supportive Role in Symptom Management

The primary application of this medication is to provide supportive relief when symptoms related to physical discomfort create noticeable physiological strain, such as slowness of movement and muscle stiffness. This use helps address symptom clusters that may become intense or disruptive. For patients already on levodopa, Aidex is applied in scenarios where additional management of discomfort is required when symptoms become more disruptive during flare-ups.

Aidex provides support that helps ease the overall symptom burden, assists with maintaining functional stability, and contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Motor Symptoms
Symptom Focus Slowness, Stiffness, and Fluctuating Manifestations
Primary Use Context Initial Therapy and Supportive Combination Therapy

Regulatory References

  1. European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Aidex (Rasagiline)

The official eligibility for Aidex is strictly defined by regulatory documents based on a patient's age, organ function, and current medication regimen. The medicine is indicated for use in the adult population, including the geriatric age group, and no special precautions are required for patients with renal impairment.


Absolute Contraindications

Use is prohibited for patients with:

  • Severe Hepatic Impairment.
  • Known Hypersensitivity to rasagiline or any of its excipients.
  • Concomitant use with any other Monoamine Oxidase (MAO) inhibitors.
  • Concomitant use with specific medications, including meperidine, tramadol, and dextromethorphan.

Use Restrictions and Limitations

Eligibility is conditional for certain groups:

  • Mild Hepatic Impairment: Use is permitted, but the daily dose must not exceed 0.5 mg.
  • Moderate Hepatic Impairment: Use is generally avoided.
  • Pediatric Population: The medicine is not recommended for use in children and adolescents, as safety and efficacy are not established in this age group.
  • Pregnancy and Lactation: Use is preferably avoided during pregnancy, and caution is advised during breastfeeding.

What should I know about interactions with other medicines?

The Aidex Continuous Glucose Monitoring System (CGMS) is a medical device and not a pharmaceutical product; therefore, its official interaction profile is defined by physical and electromagnetic interference, rather than drug-drug interactions involving pharmacokinetics or pharmacodynamics. Users must be aware of device performance considerations during specific medical procedures or in the presence of certain substances.

Medical Procedures and Device Interference

Procedure/Condition Constraint/Classification
Magnetic Resonance Imaging (MRI) Removal Required: The sensor and transmitter must be completely removed before undergoing an MRI scan.
CT Scans, X-rays Removal Required: The system must be removed before medical procedures involving powerful magnetic or electromagnetic radiation to ensure accuracy.
Other Implantable Devices (e.g., Pacemaker) Not Evaluated: The performance of the CGMS has not been evaluated when used concurrently with another implantable medical device.

Potential Substance Interference

Interactions documented for continuous glucose monitors generally involve substances that can interfere with the electrochemical reaction of the sensor. For Aidex, specific interference warnings are limited, but the following general factors can lead to inaccurate glucose readings:

  • Severe Dehydration: Excessive loss of water may result in inaccurate sensor results.
  • High Blood Components: Blood hematocrit levels outside the range of 30% to 55%, or high levels of substances like triglycerides (above 46.9 mmol/L) or cholesterol (above 12.9 mmol/L) may cause inaccurate blood glucose meter readings when checking the sensor against a blood sample.

Mechanism of Action

️ How Aidex Works

Irreversible Blockade of Dopamine Metabolism

Aidex operates as a selective irreversible inhibitor of the Monoamine Oxidase Type B (MAO-B) enzyme. MAO-B is a catabolic enzyme primarily located in the glial cells of the central nervous system (CNS) motor centers. The compound forms a permanent covalent bond with the enzyme, rendering it inactive. By blocking MAO-B, the compound prevents the oxidative breakdown of the neurotransmitter dopamine and other substrates.

Sustained Augmentation of Dopamine Signaling

This enzyme inactivation initiates a cascade that leads to the preservation and sustained accumulation of endogenous dopamine in the extracellular fluid and synaptic space. The chronic, stable elevation of functional dopamine in the brain's motor pathways augments dopaminergic neurotransmission. The resulting physiological change is the modulation of CNS motor pathway activity. Because the inhibition is permanent, the effect's duration is determined by the slow rate of new enzyme synthesis in the body, not by the drug's short plasma half-life.

Potential Non-Enzymatic Cell Modulation

Beyond its primary action, the molecule's unique chemical structure may engage pathways independent of MAO-B. Preclinical studies suggest it can modulate cellular survival and anti-apoptotic signaling, such as activating the Bcl-2 protein and the Akt/Nrf2 pathway. This domain is linked to a putative anti-oxidant physiological consequence by modulating cellular viability pathways and influencing the dynamics of oxidative stress. This domain is exerted in parallel with the primary enzyme-inhibition effect.

Dosage and Administration Information

Aidex (rasagiline) is supplied as an oral tablet and must be administered exclusively by mouth. The instructions for use are based on whether the medicine is taken alone or in combination with levodopa, but the dosage is restricted to once daily. The tablet may be taken at any time of day, with or without food.


Standard Labeled Dosing and Frequency

Regimen Starting Dose Maximum Daily Dose
Monotherapy 1 mg once daily 1 mg once daily
Adjunct with Levodopa 0.5 mg once daily 1 mg once daily

When used as adjunct therapy, the initial dose is 0.5 mg, which may be increased to 1 mg if required. The maximum permitted dose for all uses is 1 mg once daily.


Population and Contextual Constraints

Dose modifications apply to certain conditions. The dose must not exceed 0.5 mg once daily for patients with mild hepatic impairment or for those taking certain strong CYP1A2 inhibitors, such as ciprofloxacin. No dose adjustment is required for older adults or in cases of mild to moderate renal impairment. If a dose is missed, the standard procedure is to skip the missed dose entirely and take the next dose at the regularly scheduled time; doubling doses is prohibited.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 3 Clinical Trials

Research has investigated the drug's profile and use in clinical trials. The main Phase 3 trials focused on evaluating the drug's use in individuals with active disease, with a typical duration of 12 to 24 weeks.

  • Mobility and Pain Measures: Studies evaluated whether the drug was associated with changes in mobility and whether participants reported a reduction in joint pain. The primary endpoint analysis of the Phase 3 trials indicated that the drug's use was associated with greater reported improvements in standard clinical measures compared to a placebo group.
  • Long-term Follow-up: Extended follow-up research has explored the drug's use in individuals who have not responded to traditional therapies. These analyses typically involved participants from the initial trials who elected to continue using the drug. Data from trials also examined whether the drug was associated with changes in the rate of disease progression.

Post-Marketing Studies and Registries

Additional research has been conducted using large, observational patient registries to gather data on the drug's use outside of controlled clinical trials. These types of studies are observational and cannot establish cause-and-effect.

  • Real-World Outcomes: One analysis focused on whether outcomes differed between participants with mild and moderate disease activity. Researchers have investigated whether combining the drug with physical therapy was associated with changes in long-term disability.
  • Timing of Use: Research has examined whether the time between diagnosis and the start of drug use affected study outcomes.
  • Safety Monitoring: Studies monitored the drug's profile during long-term use in adult participants, documenting the occurrences and characteristics of reported adverse events.

Frequently Asked Questions (FAQ)

Common questions about Aidex (FAQ)


Q: What is the main purpose of Aidex beyond what it treats?

A: Preclinical studies suggest that, in addition to blocking the MAO-B enzyme, the medicine may also act as an activator of a protein called Bcl-2. This action is linked to cellular pathways that support cell survival. Official documents note this as a potential neuroprotective activity, although its role in patient treatment is still under investigation.


Q: What is the mechanism of action of Aidex described as in simple terms?

A: Aidex is described in official documents as working by permanently blocking an enzyme in the brain known as Monoamine Oxidase-B (MAO-B). By blocking MAO-B, the medicine prevents the natural breakdown of the neurotransmitter dopamine. This results in more dopamine remaining available in the brain to help improve motor function.


Q: Does Aidex work by preventing a problem or by relieving existing symptoms?

A: Clinical studies indicate the drug provides an immediate benefit by managing existing symptoms related to motor control. Some research findings suggest that starting the medication earlier may lead to a greater sustained clinical benefit compared to delaying its introduction.


Q: Can Aidex interact with common over-the-counter cold and flu medications?

A: Yes, official warnings emphasize that Aidex is strictly contraindicated with many common ingredients found in over-the-counter cold and flu medications. Due to the risk of severe blood pressure spikes or Serotonin Syndrome, this includes products containing dextromethorphan, ephedrine, or certain strong pain relievers.


Q: Do studies suggest Aidex maintains its effect over long periods of use?

A: Long-term follow-up studies have suggested that patients who begin treatment earlier continue to maintain a greater clinical benefit over time compared to those whose treatment was delayed.


Q: Which regulatory body first approved Aidex for use in major countries?

A: Official records show that the active substance in Aidex, rasagiline, was first approved in Europe by the European Medicines Agency (EMA) in February 2005. It subsequently received approval from the U.S. Food and Drug Administration (FDA) in May 2006.


Q: Does body weight or age affect how Aidex is described to work in the body?

A: Official product information states that no special dose adjustments are required for older adults with normal liver function. The regulatory filing documents do not specify a relationship between a patient's body weight and the medicine's pharmacological activity in the body.


Q: Are there any common lifestyle factors that can affect how Aidex works?

A: Yes, there are lifestyle factors that can affect how the medicine works. Eating high amounts of tyramine-rich foods, such as aged cheeses and cured meats, can cause a dangerous spike in blood pressure. Official warnings state that these foods should be avoided. Nicotine use may also interact with the drug and may necessitate a dosage adjustment.


Q: What are the most commonly reported side effects of Aidex?

A: According to clinical trial data, the most commonly reported side effects include headache, joint pain, flu-like symptoms, and stomach upset. Patients also reported occurrences of dizziness or lightheadedness.


Q: How long do common side effects from Aidex usually last after starting treatment?

A: For some effects, such as dizziness or lightheadedness upon standing (orthostatic hypotension), reports suggest they are more commonly experienced during the first two months of therapy. The official regulatory summaries do not specify a typical duration for other common side effects.


Q: Is there a list of rare but potentially serious side effects associated with Aidex?

A: Official warnings list several serious effects. These include the risk of Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS), and changes in impulse control, such as increased sexual urges or compulsive gambling. Regulatory documents also note an increased risk of melanoma.


Q: What should a person know about managing mild side effects while taking Aidex?

A: Specific management advice is provided for dizziness upon standing, where guidance includes standing up slowly after sitting or lying down. For any other mild side effects that are bothersome or persistent, official documents recommend seeking guidance from a qualified healthcare professional.


Q: Can Aidex cause fatigue or drowsiness, and how common is that?

A: Yes, drowsiness and fatigue are reported side effects of the medicine. Official warnings note that the drug can potentially cause significant sleepiness, including sudden onset of sleep without warning.


Q: Are there any specific supplements or vitamins that may interact with Aidex?

A: Official regulatory warnings emphasize the importance of discussing all supplements, vitamins, and herbal products with a healthcare provider. This is because they can potentially interact with Aidex and affect its performance.


Q: What is the official guidance on consuming alcohol while undergoing treatment with Aidex?

A: Regulatory guidance indicates that patients should avoid or limit the use of alcohol while taking this medicine. Consuming alcohol may increase reported side effects such as dizziness, drowsiness, and confusion.


Q: How quickly can a person expect Aidex to start having a noticeable effect?

A: Studies indicate that measurable beneficial effects on symptoms have been reported within one week of starting treatment. This timeline is observed regardless of whether the medicine is used alone or in combination with other treatments.


Q: What is considered the 'full therapeutic effect' timeframe for Aidex?

A: The primary clinical trials that established the medicine’s effectiveness assessed the drug over a period of 12 weeks. Significant improvements in symptoms were observed during this time frame.


Q: What kind of monitoring or check-ups are typically advised when starting Aidex?

A: Official warnings note an increased risk of melanoma associated with this drug class. Therefore, official warnings state that regular check-ups with a dermatologist are generally recommended to monitor the skin for changes.


Q: Are there any specific medical tests required before a person can start taking Aidex?

A: Yes, because the appropriate starting dose is conditional on a person’s liver function, testing to determine the extent of hepatic impairment is necessary before starting treatment.


Q: Is it necessary to avoid specific activities, like driving, when taking Aidex?

A: Regulatory guidance states that activities like driving or operating machinery should be avoided until patients understand precisely how the drug affects them, due to risks like sudden sleep onset, dizziness, and impaired coordination.


Q: Do official documents mention any potential for dependence or withdrawal with Aidex?

A: Official documents warn that abruptly stopping the medicine may lead to a withdrawal syndrome. Potential symptoms can include fever, muscle stiffness, or changes in consciousness.


Q: Does Aidex have any known interaction warnings with herbal remedies?

A: Yes, the use of St. John’s wort, which is a common herbal supplement, is specifically contraindicated (prohibited) while taking this medicine due to the risk of serious side effects.


Q: Can Aidex affect sleep patterns, according to reported evidence?

A: Yes, official lists of side effects include reported occurrences of trouble sleeping, abnormal dreams, and the risk of sudden onset of sleep or extreme drowsiness.


Q: What is the half-life of Aidex described as in medical sources?

A: Regulatory sources, specifically the clinical pharmacology sections, report that the elimination half-life of the drug in the blood is approximately 3 hours. The sustained therapeutic effect lasts longer because the enzyme inhibition itself is permanent.

How should Aidex be stored and disposed of?

Aidex (rasagiline) tablets must be stored according to regulatory requirements to ensure product stability and patient safety.

Storage Requirements

Item Requirement
Temperature Store at Controlled Room Temperature (20^circC to 25^circC or 68^circF to 77^circF).
Protection Keep the container tightly closed, protected from light and excess moisture.
Safety Keep this and all drugs out of the reach of children and out of sight.

Disposal

Unused or expired Aidex should be disposed of using a community drug take-back program or an authorized collection site. Disposal via wastewater or general household waste is generally discouraged by regulatory authorities. If a take-back program is unavailable, U.S. guidance permits mixing the medication with an undesirable substance and placing it in a sealed container before disposal in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aidex found in:

A-Z Index: